(NASDAQ: PAHC) Phibro Animal Health's forecast annual revenue growth rate of 3.61% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 6.34%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.06%.
Phibro Animal Health's revenue in 2026 is $1,540,974,000.On average, 5 Wall Street analysts forecast PAHC's revenue for 2027 to be $65,490,385,639, with the lowest PAHC revenue forecast at $62,648,273,429, and the highest PAHC revenue forecast at $67,723,473,804. On average, 5 Wall Street analysts forecast PAHC's revenue for 2028 to be $67,845,278,613, with the lowest PAHC revenue forecast at $64,597,150,373, and the highest PAHC revenue forecast at $70,443,781,205.
In 2029, PAHC is forecast to generate $69,428,741,130 in revenue, with the lowest revenue forecast at $66,708,433,729 and the highest revenue forecast at $71,458,821,280.